Phagenesis, a UK-based medical device company focused on the treatment of dysphagia, has expanded its series B round to $17m. It originally announced a €7m ($9.1m) first close led by Inventages, a life sciences firm backed by Switzerland-based food and nutrition corporation Nestlé, in autumn 2011. Founded in 2007 after it spun off from research performed at the University of Manchester, Phagenesis raised £2m ($3m) in a September 2010 series A round of financing from unnamed investors. Phagenesis is developing a device that will help dysphagia sufferers to swallow, using controlled electrical pulses.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?